Oncoinvent is developing therapeutics to combat various cancers. 

Oncoinvent’s lead product candidate, Radspherin®, is a novel alpha-emitting radioactive micro particle suspension designed for local treatment of metastatic cancers in body cavities. Radspherin® consists of an alpha radiating micro particle suspension that is instilled in the targeted body cavity. This allows local radiopharmaceutical therapy of that body cavity, without the need to use systemic administration. As such, our method is a uniquely local approach that avoids exposing healthy tissue to radiation, thus avoiding side effects. Radspherin® has in animal models been shown to cause a reduction in tumor cell growth and a significant increased survival. Also, clinical phase 1/2a studies have shown very promising results both in terms of excellent safety data and in terms of long-term avoidance of cancer recurrence [published long-term data], which is the primary efficacy parameter in phase 2b and phase 3 studies.  

It is anticipated that the product can potentially treat several forms of cancer. The first clinical indication for Radspherin® currently pursued is the treatment of Peritoneal Carcinomatosis, or PC for short, originating from ovarian cancer and colorectal cancer. Peritoneal Carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

A successful development of Radspherin® will present a novel treatment modality for a large group of patients who currently have very few treatment options with severe side effects, and a poor prognosis.


Oncoinvents lead product candidate is designed to treat cancer in the peritoneal cavity

Description of the product

  • Inorganic microparticles as carriers of alpha-emitters
  • High-power radiation with a short range
  • Short half-life of the radionuclide
  • Microparticles which degrade slowly in the body
  • Regional retention of effective radiation dose

See Expanded Access Policy

Anders Månsson

Chief Executive Officer


Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.